Agreements reached under this partnership
Business alliances- 1
Agreement on the basic terms of a U.S. sales partnership
- 2
Discussing the detailed terms of the exclusive sales license agreement
- 3
Review of the sales strategy, supply plan and contractual terms
- 4
Discussions regarding the scope of responsibilities and cost sharing associated with increasing production capacity, among other matters.
- 5
The initial shipment is scheduled for delivery to Terrain in November
- 6
Sales are scheduled to begin promptly after the sales license agreement is executed
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
Because the revenue outlook for the product remains uncertain, there will be no change to the earnings forecast for the fiscal year ending December 2026 as a result of this matter. The company will promptly disclose any impact once it becomes known.
| Item | Details |
|---|---|
| Name of alliance partner | Terrain Pharmaceuticals |
| Alliance partner's business activities | A U.S. specialty pharmaceutical company with more than 10 years of experience developing and marketing topical analgesics. Through a nationwide distribution network that includes independent retail pharmacies, specialty pharmacies and healthcare institutions, it markets prescription and over-the-counter topical patches and semisolid formulations, including lidocaine- and NSAID-based products. |
| Alliance partner's location | Reno, Nevada, U.S. |
| Type of alliance | Business alliances |
| Details of the alliance | Agreement on the basic terms of a U.S. sales partnership, Discussing the detailed terms of the exclusive sales license agreement, Review of the sales strategy, supply plan and contractual terms, Discussions regarding the scope of responsibilities and cost sharing associated with increasing production capacity, among other matters., The initial shipment is scheduled for delivery to Terrain in November, Sales are scheduled to begin promptly after the sales license agreement is executed |
| Contract Date | Expected sometime in 2026 (sales license agreement) |
| Alliance start date | May 2026 (agreement on the basic terms of the sales partnership) |
| Impact on Business Performance | Because the revenue outlook for the product remains uncertain, there will be no change to the earnings forecast for the fiscal year ending December 2026 as a result of this matter. The company will promptly disclose any impact once it becomes known. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Time is being required to review and discuss the sales strategy, supply plan and contractual terms in order to reflect in the agreement the scope of responsibilities and cost sharing associated with increasing production in anticipation of higher sales volumes.